Universal Biosensors, Inc. (ASX:UBI)

Australia · Delayed Price · Currency is AUD

0.0140

0.00 (0.00%)

Feb 13, 2026, 4:25 AM AEST

-90.00% (1Y)

Market Cap	4.17M -90.0%
Revenue (ttm)	5.95M -16.5%
Net Income	-17.46M
EPS	-0.06
Shares Out	298.07M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	132,045
Open	0.0140
Previous Close	0.0140
Day's Range	0.0130 - 0.0140
52-Week Range	0.0120 - 0.1600
Beta	0.21
Analysts	n/a
Price Target	n/a
Earnings Date	Aug 17, 2026

About Universal Biosensors

Universal Biosensors, Inc., through its subsidiaries, designs and develops electrochemical cells (strips) used in conjunction with point-of-use devices in Australia, the Americas, Europe, and internationally. The company manufactures and distributes Prothrombin Time International Normalized Ratio coagulation test strips and Xprecia Stride and Xprecia Prime medical devices to monitor the effect of the anticoagulant therapy warfarin; and Sentia wine testing products, such as free SO₂, malic acid, glucose, fructose, total acid, and titratable acid... [Read more]

Industry Medical Devices

Sector Healthcare

Founded 2001

Employees 76

Stock Exchange Australian Securities Exchange

Ticker Symbol UBI

Full Company Profile

Financial Performance

In 2024, Universal Biosensors's revenue was 6.28 million, a decrease of -5.28% compared to the previous year's 6.63 million. Losses were -14.24 million, 111.2% more than in 2023.

Financial Statements